499 related articles for article (PubMed ID: 27012367)
1. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.
Paul S; Lal G
Int J Cancer; 2016 Sep; 139(5):976-85. PubMed ID: 27012367
[TBL] [Abstract][Full Text] [Related]
2. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
[TBL] [Abstract][Full Text] [Related]
3. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
4. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
Gomes AQ; Martins DS; Silva-Santos B
Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
[TBL] [Abstract][Full Text] [Related]
5. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
7. Porcine T lymphocytes and NK cells--an update.
Gerner W; Käser T; Saalmüller A
Dev Comp Immunol; 2009 Mar; 33(3):310-20. PubMed ID: 18601948
[TBL] [Abstract][Full Text] [Related]
8. CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells.
Haas JD; González FH; Schmitz S; Chennupati V; Föhse L; Kremmer E; Förster R; Prinz I
Eur J Immunol; 2009 Dec; 39(12):3488-97. PubMed ID: 19830744
[TBL] [Abstract][Full Text] [Related]
9. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
[TBL] [Abstract][Full Text] [Related]
10. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
Li Y; Li G; Zhang J; Wu X; Chen X
Front Immunol; 2020; 11():619954. PubMed ID: 33664732
[TBL] [Abstract][Full Text] [Related]
11. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
12. Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases.
Lopez RD
Immunol Res; 2002; 26(1-3):207-21. PubMed ID: 12403359
[TBL] [Abstract][Full Text] [Related]
13. Potential of human gammadelta T lymphocytes for immunotherapy of cancer.
Kabelitz D; Wesch D; Pitters E; Zöller M
Int J Cancer; 2004 Dec; 112(5):727-32. PubMed ID: 15386388
[TBL] [Abstract][Full Text] [Related]
14. Distinct metabolic programs established in the thymus control effector functions of γδ T cell subsets in tumor microenvironments.
Lopes N; McIntyre C; Martin S; Raverdeau M; Sumaria N; Kohlgruber AC; Fiala GJ; Agudelo LZ; Dyck L; Kane H; Douglas A; Cunningham S; Prendeville H; Loftus R; Carmody C; Pierre P; Kellis M; Brenner M; Argüello RJ; Silva-Santos B; Pennington DJ; Lynch L
Nat Immunol; 2021 Feb; 22(2):179-192. PubMed ID: 33462452
[TBL] [Abstract][Full Text] [Related]
15. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells.
Urban EM; Chapoval AI; Pauza CD
Clin Dev Immunol; 2010; 2010():732893. PubMed ID: 20396597
[TBL] [Abstract][Full Text] [Related]
16. gammadelta-T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-gamma response to Plasmodium falciparum malaria.
D'Ombrain MC; Hansen DS; Simpson KM; Schofield L
Eur J Immunol; 2007 Jul; 37(7):1864-73. PubMed ID: 17557374
[TBL] [Abstract][Full Text] [Related]
17. γδ T cell-based anticancer immunotherapy: progress and possibilities.
Meraviglia S; Lo Presti E; Dieli F; Stassi G
Immunotherapy; 2015; 7(9):949-51. PubMed ID: 26569071
[No Abstract] [Full Text] [Related]
18. Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy.
Chabab G; Barjon C; Bonnefoy N; Lafont V
Front Immunol; 2020; 11():2186. PubMed ID: 33042132
[TBL] [Abstract][Full Text] [Related]
19. Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.
Bartish M; Del Rincón SV; Rudd CE; Saragovi HU
Front Immunol; 2020; 11():564499. PubMed ID: 33133075
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy with γδ T cells: many paths ahead of us.
Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
